Skip to Content
Search Menu

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

The DESTINY-Breast11 trial showed that anthracycline-free T-DXd-THP improved response rates and safety compared with standard therapy in high-risk HER2-positive early breast cancer.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

ESMO 2025: Advancements to improve patient outcomes and quality of life in Immunotherapy

/ Christina Ruhlmann
ESMO25 Play the Video 4:45

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
Bladder cancerESMO25 Play the Video 04:57

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Jan Andreasen
ESMO25Prostate cancer

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

/ Danny Rischin
ESMO25Skin cancer Play the Video 03:46

ESMO 2025: The Future of Oncology Will Be Built by Individuals

/ Jan Andreasen
ESMO25

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
Breast cancerESMO25
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
Breast cancer Play the Video 06:19
Dimitrios Salgkamis

ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

/ Dimitrios Salgkamis
Breast cancerNBCN Play the Video 05:35
Anders Winther Mølby Nielsen

New Data Support Boost in ER-/HER2- Breast Cancer

/ Anders W. Mølby Nielsen
Breast cancerNBCN Play the Video 08:40
Back to top